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Abstract 
Introduction 
A high BMI during and after pregnancy is linked to poor pregnancy outcomes, and contributes 
to long-term maternal obesity, hypertension and diabetes. Evidence of feasible, effective 
postnatal interventions is lacking.  This randomised controlled trial will assess the feasibility 
of conducting a future definitive trial to determine effectiveness and cost effectiveness of 
lifestyle information and access to Slimming World®(Alfreton, UK) groups for 12 weeks 
commencing from 8 to 16 weeks postnatally, in relation to supporting longer-term postnatal 
weight management in women in an ethnically diverse inner-city population.  
Methods/analysis 
Women will be recruited from one maternity unit in London. To be eligible, women will be 
overweight (BMI 25–29.9 kg/m²) or obese (BMI ≥30 kg/m²) as identified at their first antenatal 
contact, or have a normal BMI (18.5-24.9 kg/m2) at booking but gain excessive gestational 
weight as assessed at 36 weeks gestation.  Women will be aged 18 and over, can speak and 
read English, expecting a single baby and will not have accessed weight management groups 
in this pregnancy.  Women will be randomly allocated to standard care plus lifestyle 
information and access to Slimming World®(Alfreton, UK)  groups or standard care only.  A 
sample of 130 women is required.  
Feasibility trial objectives reflect those considered most important inform a decision about 
undertaking a definitive future trial.  These include estimation of impact of lifestyle 
information and postnatal access to Slimming World®(Alfreton, UK)  on maternal weight 
change between antenatal booking weight and  weight at 12 months post-birth, recruitment 
rate and time to recruitment, retention rate, influence of lifestyle information and Slimming 
World®(Alfreton, UK)  groups on weight management, diet, physical activity, breastfeeding, 
smoking cessation, alcohol intake, physical and mental health, infant health, health-related 
quality of life 6 and 12 months postnatally.  An embedded process evaluation will assess 
acceptability of study processes and procedures to women.   
Ethics/dissemination. London–Camberwell St Giles Research Ethics Committee, reference: 
16/LO/1422.  Outcomes will be disseminated in peer reviewed journals and presentations at 
national and international conferences. 
Trial registration number: ISRCTN 39186148 
Protocol version number: v7, 13/08/17 
Trial sponsor: King’s College London 
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Strengths and limitations of this study 
 Postnatal interventions may be more effective than antenatal interventions at 
supporting weight management among women with higher BMIs but evidence is 
needed. 
 This feasibility trial will assess if women with high BMIs at pregnancy commencement 
or have normal BMIs but gain excessive gestational weight would be prepared to be 
randomised to standard care plus Slimming World®(Alfreton, UK)  groups offered from 
8 to 16 weeks postnatally, or to standard care only. 
 Women will only be recruited from one study site, however the site provides 
maternity care to a population with wide diversity.  The intervention is available UK-
wide. 
 Blinding of study participants and assessors is not possible. 
 
Introduction  
At around 6 to 8 weeks postnatally, two thirds of women weigh more than their pre-
pregnancy weight1, with evidence that women who commence subsequent pregnancies 
overweight or obese have higher risk of adverse outcomes for themselves and/or for their 
infants. Furthermore, a high BMI before, during and after pregnancy is linked to poor 
maternal health behaviours including smoking, lack of regular exercise and not 
breastfeeding2,3,4.  Maintaining a high BMI postnatally is an important predictor of maternal 
future weight gain and obesity, hypertension, diabetes and degenerative joint disease 5,6,7, 
with infants of obese women at greater risk of higher BMI and blood pressure in childhood 
and young adulthood4.  In the absence of evidence to support the benefit of  pregnancy 
weight management interventions and positive lifestyle behaviours, postnatal interventions 
are viewed as increasingly important8,9 in terms of enhancing life-course health, and 
preventing adverse outcomes in subsequent pregnancies, but knowledge of how best to 
support and treat overweight or obese individuals, including postnatal women, remains a 
challenge 10,11. The timing of commencement, recruitment approaches and content of 
postnatal interventions are unclear5, including how best to ensure that socio-economic 
influences which may impact on maternal health and lifestyle behaviours are considered.  This 
is important, as a significantly greater proportion of women from areas of high social 
deprivation in the UK have weight management problems12, findings supported with work 
from the USA where excessive pregnancy weight gain and failure to lose weight were found 
to be highly prevalent among young, low income, ethnic minority women in one large cohort 
study13.  
 
Although around half of all UK women of reproductive age are overweight or obese14, UK 
public health guidance does not recommend dieting and weight loss during pregnancy due to 
concerns about impact on infant outcomes15 despite lack of evidence 16, and there is no 
current UK guidance on recommended pregnancy weight gain. Pregnancy only interventions 
have measured impact on adverse outcomes including gestational diabetes, large for 
gestational age infants and caesarean births 17,18,19,20. UPBEAT, a UK based multi-centre trial 
of a behavioural intervention based on changing diet to foods with a lower glycaemic index 
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and increasing physical activity, aimed to reduce risk of gestational diabetes and large for 
gestational age infants21; 1555 women with a mean BMI of 36.3 kg/m2 (SD 4.8) were 
recruited.  No differences were found in incidence of outcomes of interest.  Gestational 
diabetes was reported in 172 (26%) women in standard care compared with 160 (25%) in the 
intervention group (risk ratio 0.96, 95% CI 0.79–1.16; p=0.68). Sixty-one (8%) of 751 babies in 
the standard care group were large for gestational age compared with 71 (9%) of 761 in the 
intervention group (1.15, 0.83–1.59; p=0.40). 
 
Recent systematic reviews of postnatal interventions have highlighted the potential 
importance of these, but reported gaps in evidence of ‘what works’ and the low quality of 
evidence. A Cochrane review of diet and/or exercise for postnatal weight reduction22 in which 
12 trials contributed data on 910 women, found women who exercised did not lose 
significantly more weight than women in usual care groups (two trials, n=53, mean difference 
-0.10kg, 95% CI -1.90 to 1.71), but women who took part in a diet (one trial, n=45, mean 
difference -1.70kg, 95% CI -2.08 to -0.132) or diet plus exercise programme (seven trials, 
n=573, mean difference -1.93kg, 95% CI -2.96 to -0.89) lost significantly more weight than 
women in usual care groups. Trials included women who were obese, overweight or gained 
excessive gestational weight, with recruitment from three weeks to 24 months postpartum. 
Intervention duration ranged from 10 to 24 weeks, with content often delivered as a 
‘package’. Only one trial was from the UK. Despite considerable study heterogeneity, the 
authors suggested diet and exercise together rather than diet alone could help women to lose 
weight postnatally because the former could improve women’s cardiovascular fitness level 
and preserve fat-free mass. 
 
van der Pligt and colleagues completed a systematic review of interventions to reduce 
postpartum weight retention across all BMI categories5.  Studies were included if postpartum 
weight was a primary outcome, and diet and/or exercise and/or weight monitoring were 
intervention components. Interventions commenced from 11 days to nine months 
postpartum and included counselling, individualised physical activity plans, healthy eating 
groups, clinic visits. Of 11 studies included, 10 were RCTs, none from the UK. Seven reported 
a decrease in postpartum weight retention, six of which included diet and physical activity 
delivered by different health professionals.  No study considered cost effectiveness, with wide 
heterogeneity in intervention implementation. Nevertheless, findings suggested that 
postnatal weight loss was achievable, although evidence of optimal setting, implementation, 
intervention duration and recruitment approach was unclear.  
 
The potential for postnatal interventions to impact on other maternal health behaviours was 
considered in a review by Hoedjes et al23 which also reported poor quality evidence.  Eight of 
17 included studies assessed effects on weight loss, and nine on smoking cessation and 
relapse prevention. Of the weight loss studies, five reported significant effects of combined 
diet and exercise. Two of the four studies which assessed smoking relapse prevention found 
no evidence of effect. Four studies included interventions for smoking prevention and 
prevention of relapse.  Although authors recommended that existing postpartum lifestyle 
interventions could support weight loss, smoking cessation or prevent smoking relapse, 
caution is needed. There was wide variability in study methods, and details of study selection, 
data extraction processes and assessment of study quality were not provided. 
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The potential for the postnatal period to be a more appropriate time to consider support for 
weight management and positive lifestyle behaviours is clear, yet high quality evidence of 
effective interventions is lacking. Based on evidence from general population studies, that 
commercial organisations may be more effective at supporting weight management than 
healthcare providers24, this trial is being undertaken to assess the feasibility of conducting a 
future definitive RCT to determine effectiveness and cost effectiveness of lifestyle 
information and access to Slimming World®(Alfreton, UK)  groups for a 12 week period, from 8 
to 16 weeks postnatally, on long-term postnatal weight management and positive lifestyle 
behaviour among women from an ethnically diverse inner city population.   
 
 
Objectives 
 
The following are the specific trial feasibility and trial process objectives to inform if a future 
definitive trial could be undertaken.  Findings will inform if postnatal women would be 
prepared to enter a study of weight management, when would be an optimal time to 
intervene, content of a pragmatic and accessible intervention, if an intervention could impact 
on other health areas, and outcomes likely to be of most importance in a future trial.  
 
Trial feasibility objectives 
 
 assess recruitment and  retention rates 
 estimate the effect size for a likely primary study outcome in a future definitive trial, 
namely difference between study groups in weight change from booking to 12 months 
post-birth, expressed as % weight change or weight loss in kilograms.  
 estimate impact of lifestyle information and access to Slimming World®(Alfreton, UK)  
groups on maternal weight change from first antenatal visit to 12 months postnatally 
 explore influence of lifestyle information and access to Slimming World®(Alfreton, UK)  
groups including weight management, diet, physical activity, breastfeeding, smoking 
cessation, alcohol intake, physical and mental health, infant health, sleep patterns, 
body image, self-esteem and health-related quality of life at 6 and 12 months 
postnatally 
 assess resource impacts across different agencies likely to be of relevance and identify 
data appropriate for economic evaluation in a definitive RCT 
 decide if criteria to inform progression to a definitive RCT have been met  
 
 
 Trial process evaluation objectives 
 
 assess acceptability of trial procedures and intervention 
 assess variation in Slimming World®(Alfreton, UK)  groups attended by women 
 assess sources of weight management support accessed by women (in particular 
assess risk of contamination) 
 
 
 
<INSERT TABLE 1> 
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Methods and analysis 
 
This protocol paper has been written following SPIRIT and TIDieR guidance 25,26 
 
 
Study design 
 
A single centre, randomised two arm feasibility trial, with a nested mixed-methods process 
evaluation. 
 
Setting 
 
 One maternity unit in inner city London, serving an ethnically diverse population, and 
providing maternity care for over 6,000 women annually. 
 
Target population 
 
Women overweight (BMI 25–29.9 kg/m²) or obese (BMI ≥30 kg/m²) as identified at their 
first antenatal contact and women with a normal BMI (18.5-24.9 kg/m2) at pregnancy booking 
who gain excessive gestational weight as assessed at 36 weeks gestation27.  Women will be 
eligible for recruitment if they meet these criteria: 
 
 Aged 18 and over 
 Speak and read English 
 Expecting a single baby 
 Have not accessed weight management groups during index pregnancy.   
 
Exclusion criteria  
 <18 years old 
 Insufficient understanding of spoken and written English  
 Current diagnosis of major psychiatric disorder  
 Fetus has known abnormality 
 Involvement in another postnatal study to reduce ‘burden’ of research participation 
 Identified medical complications (for example cardiac disease, type 1 diabetes).  
 Identified eating disorders 
 Previous surgery for weight management 
 
Recruitment 
 
Women with BMIs≥25 will be identified from their antenatal booking details.  At 
approximately 26 weeks gestation, identified women in this group will receive a study letter 
which briefly explains study aims and advises that a Research Midwife will be in contact within 
two weeks to explain the study further.  The letter will also explain how the woman can 
contact researchers if she does not want to receive further details.  The Research Midwife will 
call women who have not asked to be removed from the contact list.    
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Women with normal BMIs at pregnancy commencement, but gain excess pregnancy weight 
as assessed at around 36 weeks gestation against IoM criteria27 will be offered the 
opportunity to self-refer to the Research Midwives, through advertising at the study site and 
midwifery and obstetric referrals (from around 28 weeks gestation). Women will be asked to 
contact the Research Midwives to arrange to be weighed at around 36 weeks gestation.  If 
women in this group do not respond to study advertising within three months of 
commencement of recruitment, a similar opt-out approach for women with high BMIs will be 
adopted, following relevant ethics amendments. An opt-out letter would be sent to all women 
with normal BMI at booking at around 32-34 weeks gestation to explore feasibility of this 
approach.  
 
All women identified will be offered a Patient Information Leaflet by Research Midwives prior 
to seeking consent at around 36 weeks gestation.  Women interested in participating will be 
met by Research Midwives at the study site to obtain consent and complete the baseline 
questionnaire.  Women who gain excessive gestational weight could be recruited at an 
antenatal appointment if this takes place around 36 weeks gestation.  
 
All women who are eligible, recruited and provide written consent will be randomised to 
either:  
 
 standard care plus lifestyle information and postnatal access to Slimming World 
®(Alfreton, UK) weight management groups  
 standard care only 
 
A screening form will be completed by the Research Midwife to record women approached, 
their eligibility, at what point women may have declined to take part (when first approached 
or at consent) and reasons for this, if women are willing to provide information. 
 
A separate patient information leaflet will be mailed to recruited women purposively selected 
from both trial groups and invited to participate in a telephone or face to face interview at 12 
months postnatally. Similarly, women allocated to the intervention who are purposively 
selected for interview about their experiences on completion of their Slimming 
World®(Alfreton, UK)  groups will be sent a separate study information leaflet to seek consent 
to participate in this stage of the study process evaluation. 
 
 
Treatment allocation and randomisation 
 
Randomisation and allocation will be carried out by KCL’s Clinical Trials Unit web-based 
system. Women will be registered on the InferMed MACRO web-based data entry system by 
a Research Midwife prior to randomisation to allocate each a unique study number ‘PIN’. 
Research Midwives will access the system and using the PIN, initials and date of birth, request 
randomisation. Unit of randomisation will be individual participant, allocated in a ratio of 1:1 
to intervention and control.  Selection bias will be minimised by ensuring all women eligible 
and recruited have equal opportunity of being allocated to each study group and follow up 
completed, with information on women randomised and allocated but who opt out presented 
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but clearly indicated as such. Use of intention to treat (ITT) analysis will limit attrition and 
analytical bias.  
 
Blinding 
 
It will not be possible to ‘blind’ Research Midwives or women to allocation. Those responsible 
for analysis will be blinded to allocation.  
 
Interventions 
 
Standard care (described below), plus information on positive lifestyle behaviours from late 
pregnancy and access to a 12 week weight management group (Slimming World®(Alfreton, 
UK)) commencing from 8 weeks up to 16 weeks postnatal (see figure 1 flow chart). 
 
An evidence-based positive lifestyle leaflet reflecting current NICE guidance on breastfeeding, 
diet, importance of smoking cessation/prevention of relapse, reducing alcohol, and managing 
sleep 10,28 will be offered to women allocated to the intervention.  
 
Slimming World®(Alfreton, UK)  content is underpinned by group behaviour change 
techniques targeted to support individuals make healthier food choices and increase physical 
activity (www.Slimmingworld.co.uk).  Groups are run using a standardised approach, with in-
built quality assessment procedures7. Behaviour change techniques are supported by social 
cognitive theory, with a focus on motivation and self-efficacy for weight management and 
reducing relapse, including goal setting, self-monitoring, social support, and positive 
reinforcement 29,30.  
 
Consultants who lead groups receive standardised training overseen by Slimming World 
®(Alfreton, UK) dietitians and nutritionists which includes motivational techniques to support 
positive lifestyle changes to manage weight, nutrition, food facts, and role of exercise and 
activity in health and weight management.  Groups follow a standard format, starting with a 
weigh in, followed by discussion of group member’s experiences of weight management to 
help change habits, share healthy swaps and discussions of what to eat. Sessions can include 
basic cooking skills, taking cost, cultural preferences and time constraints into account.  
 
A food optimising system encourages adherence to healthy eating and physical activity 
encouragement includes facilitation of behaviour change, redefining what ‘activity’ can 
include. Slimming World®(Alfreton, UK)  will record initial and ongoing attendance and weekly 
weight. Women can attend for up to 12 groups at no-cost, which run over 14 consecutive 
weeks to allow two ‘holiday’ weeks within offer. After this time, women can choose to 
continue and pay the standard weekly fee. 
 
A Research Midwife will contact women at 8 weeks postnatally to provide a dedicated 
Slimming World®(Alfreton, UK)  telephone number for member services.  A Slimming 
World®(Alfreton, UK)  consultant will provide the woman with information on the local groups 
she can join, times and venue (standard practice).  Women can choose which Slimming World 
group they attend and when they commence groups within the 8 to 16 week ‘window’ to fit 
with their health, lifestyle and family demands. Women can take their babies with them.  
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We will assess adherence to allocation protocols, loss to follow-up and women’s views of 
acceptability and sustainability. To capture data on whether women attend for each complete 
Slimming World®(Alfreton, UK)  group session or leave after the initial weigh-in, we will ask 
women to complete in their follow-up questionnaires how many groups they attended and 
stayed for the whole session. Follow up will capture data on women who continue attending 
groups or achieve their goal and stop attending to compare outcomes of interest with the 
control group.   
 
Slimming World’s®(Alfreton, UK)  quality assurance procedures ensure standardisation of 
weight management groups, including weekly calls between group consultants and their 
team managers.  As consultants are from the local area, they will be aware of cultural 
preferences, time and budget constraints women face, and can advise on basic cooking skills 
and local shops selling healthy foods within women’s budgets. The Food Optimising system 
used in Slimming World®(Alfreton, UK)  groups includes pictorial use of recipes for individuals 
who may not have a high level of understanding of written English.  As our postnatal 
population is geographically mobile31, women who move from the area can transfer their 
group membership to another local group anywhere in the UK.  
 
Women from both trial groups will be asked to attend an appointment with a Research 
Midwife to be weighed either at the study site or their home at 6 and 12 months. Travel costs 
and £10 Love2Shop voucher to thank women for their time will be offered. 
 
Standard care 
 
Women allocated to standard care only will receive standard NHS maternity care to 8 weeks 
postnatal.  This could include, for example, routine midwifery and health visitor contacts for 
infant feeding assessment and assessment of birth recovery.  Women will be offered a routine 
contact with their GP at around 6-8 weeks postnatally. We will ask all recruited women at 
their 6 and 12 month follow up about their experiences of using weight management groups 
or other sources of support for weight management, healthy lifestyle and activity. 
 
<INSERT FIG 1 HERE> 
 
Trial objectives 
 
Feasibility objectives reflect MRC guidelines for complex interventions32 with important 
exceptions. The aim is not to evaluate the intervention itself.  Slimming World®(Alfreton, UK)  
groups are “standardised”, with robust mechanisms to ensure intervention fidelity.  Our 
process evaluation is not designed to answer some questions seen in complex evaluations 
regarding generalizability of the intervention, assurance that implementation/delivery of the 
intervention is consistent across sites, or determine mechanisms of impact. This study reflects 
a pragmatic trial approach – evaluating the impact of an intervention where women can 
choose which group to attend, and can switch groups, exactly as if they were a ‘standard’ self-
referred member of Slimming World®(Alfreton, UK).  
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Trial feasibility objectives  
 
The primary feasibility objective is to estimate the effect size for a likely primary study 
outcome in a future definitive trial, namely difference between study groups in weight change 
from booking to 12 months post-birth, expressed as % weight change or weight loss in 
kilograms. Mean % change across all women gives greater power, and fewer women will need 
to be recruited. We will undertake pre-planned sub-group analysis of the primary assessment 
in women of different booking BMI categories. The primary endpoint for a future trial will be 
selected on grounds of power. 
 
Other objectives include those most appropriate to support meeting the primary objective 
and inform progress to a definitive RCT. These will include rates of 5% and 10% weight 
reduction and changes in relation to aspects of healthy lifestyle and health behaviours, 
including diet and nutrition, breastfeeding, physical activity, smoking cessation, alcohol 
intake, self-esteem and body image. Some included measures have been validated in relevant 
populations, including among women of reproductive age and women who have recently 
given birth.   
 
Measures will be included in questionnaires at 6 and 12 months postnatally. Those marked** 
will also be included in the baseline questionnaire.  Questionnaires will be ‘tailored’ for the 
intervention or standard care arm, to enable questions on uptake of support for weight 
management to be included at 6 and 12 months to inform trial process outcomes. 
 
 Dietary intake: The Dietary Instrument for Nutritional Education (DINE© University 
of Oxford)** 33.   
 Soft drink intake: questions developed for the study 
 Physical activity: The International Physical Activity Short-Form** 34 
 Mental health: Edinburgh Postnatal Depression Scale 35 
 Breastfeeding intent**, uptake, and duration, questions developed for study 
 Sleep patterns: questions developed for the study 
 Smoking: smoking status/cigarette dependence** 36 
 Alcohol consumption: Alcohol Use Disorders Identification Test** 37 
 Self-esteem: Rosenberg Self-Esteem Scale** 38 
 Infant health: questions developed for study 
 Impact on body image 39 
 Resource utilisation and costs outcome measures: the EQ-5D-5L** and the Adult 
Service Use Schedule** 40 
 
Trial process evaluation objectives 
The process evaluation will focus on the following key aspects: 
 
 The acceptability of study processes and procedures 
 The acceptability of the intervention and how it is experienced by women (those 
who complete at least 10/12 Slimming World®(Alfreton, UK)  groups and those who 
do not; those who complete each group attended for the full session or leave after 
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being weighed; those who continue to attend Slimming World ®(Alfreton, UK) groups 
on completing the intervention and those who do not) 
 The likely variation in groups attended by women in relation to date/time of day, 
and whether women stay with one consultant/group or try different groups. 
 Sources of weight management support control group  women may have accessed; 
additional sources of weight management support intervention group women may 
have accessed  
 
Data will be collected using questionnaires and semi-structured interviews with a sub-sample 
of women.  Questionnaires at 6 and 12 months include sections designed to capture 
information on weight management views and use of strategies among all women, and on 
Slimming World®(Alfreton, UK)  attendance, barriers and facilitators among intervention 
women only. 
 
Semi-structured qualitative interviews will be conducted at two time points with intervention 
women (n=approx. 10 -15 women at six months; 15-20 at twelve months) to explore the 
acceptability and sustainability of the intervention, and acceptability of trial procedures.  This 
will include targeting women who did and did not join Slimming World®(Alfreton, UK), and 
those who did/did not attend the 12 sessions offered, and those who did/did not lose weight.   
At 12 months, a sub-sample of control group women will also be interviewed to explore study 
processes and experiences of participating, including reasons for taking part/dropping out, 
recruitment and randomisation (expectations/understanding of the study aims), views on 
outcome measures, attendance for weighing appointments as part of study follow up and 
lifestyle behaviours.  Topic guides for both groups will be informed by the COM-B model of 
behaviour change41, exploring barriers and facilitators to weight management/the 
intervention according to capabilities, opportunities and motivations. Control group women 
will be asked about the impact, if any, of participating on their levels of physical activity or 
any dietary changes.  
 
Telephone or face to face interviews will be offered. Sampling will be based on maximum 
diversity in relation to age, parity, ethnicity, socio-economic status, and reflect the range of 
weight loss/gain of the sample.   
 
Health economics 
The health economic component will review quality and completeness of economic data 
generated by the trial itself (e.g. women’s self-report data on service contacts and quality of 
life outcomes, data from women’s maternity records) and data from external sources (e.g. 
unit cost data for costing service contacts and estimating intervention costs) necessary for 
conducting an economic evaluation in a future definitive trial.  An assessment will also be 
undertaken of suitability of existing economic models that could support additional modelling 
of longer-term (out of trial) resource impacts and health outcomes linked to observed (within 
trial) impacts on weight loss as part of a definitive trial. This will identify whether or what 
additional evidence and modelling would need to be undertaken to support evaluation of 
longer term costs and outcomes.       
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The health economic component will include primary analysis of economic data generated by 
the trial to gain preliminary insight into intervention cost-effectiveness. This will include: 
 
 Analysis of differences in overall costs between trial groups, including service contacts, 
clinical resource use and weight management intervention costs. Sub-group effects 
on differences in costs between groups will be explored with specific reference to 
baseline BMI. This, with evidence on sub-group analysis of weight loss outcomes, will 
inform whether a definitive trial should be designed to evaluate variability in 
intervention cost-effectiveness between relevant sub-groups.   
 
 A preliminary within trial cost-effectiveness analysis of the weight management 
intervention versus standard care using comparative feasibility trial data on resource 
use and costs and quality of life outcomes over a 12 month follow-up.    
 
 
Sample size calculation, selection and loss to follow up 
A sample size of 190 women will allow a 30% loss to follow up to ensure we achieve our 
required sample size of 130 women. This study is designed firstly to establish the rates at 
which women could be recruited and retained in a future definitive RCT and estimate critical 
parameters with necessary precision to inform sample size requirements. In particular, we 
require estimates of the standard deviation, and design effect for the primary endpoint, 
allowing for clustering by intervention group. 130 women will allow estimates of the required 
sample size for any given clinically important difference to within 30% of the true value.  
 
Based on published data 17,42 the mean (SD) percentage weight change following a Slimming 
World®(Alfreton, UK)  programme of 12 weekly groups is -5.5%, (3.3). Assuming these 
numbers are typical, 65 women in each group (130 in all) would be required to detect a 
difference of 2% between active and control groups with 90% power. Of around 6,600 women 
who give birth at the reference maternity unit over 12 months in 2017, 40% were overweight, 
15% of whom were obese. Data on women with excessive GWG are not routinely collated. 
Potentially 55 women booking each week would meet obese/overweight inclusion criteria. 
Recruiting 7 - 8 women each week over an 8 month (32 week) period would be sufficient to 
achieve the desired sample size to meet the aims of this feasibility study. 
 
Compliance issues are an important consideration.  Loss to follow up among postnatal women 
can range from 30% to 40% 43,44.  Experience of research in similar populations has shown 
that planned initiatives including flexible follow up appointments, travel expenses, vouchers 
for returning questionnaires and sending of reminders, can reduce loss to follow up.  Follow 
up appointments will be offered at weekends and week days, with the option to complete 
questionnaires at these appointments.  
 
 
Analysis 
 
Process data will be analysed separately before examining relationships between quantitative 
and qualitative data, with synthesis completed in line with O’Cathain45. Quantitative data will 
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be entered onto the MedSciNet web based data entry system. Retention and adherence will 
be considered from recruitment rate, consent rate, withdrawal and loss to follow-up (with 
reason), departures from randomized treatment and prevalence of SAEs reported by 
treatment group and overall. Estimated differences and 95% Confidence Intervals will be 
calculated for specified primary and secondary analyses (significance at 5%). Sensitivity 
analyses will assess robustness of conclusions to missing outcome data and departures from 
randomized treatment. Analyses of potential efficacy will be based on the ITT sample, utilising 
follow-up data from all randomised women.  
 
Differences between arms will be compared at 6 and 12 months post-birth adjusting for 
important prognostic factors (parity, maternal age, ethnicity, BMI at booking, and (as 
appropriate) baseline measurement).  Data to inform process outcomes will be evaluated 
using descriptive analysis.  Numbers (with percentages) will be presented for binary and 
categorical variables and means (standard deviations), or medians (with lower and upper 
quartiles) or geometric means for continuous variables will be presented). Stata version 15.1 
or later will be used for analyses (StataCorp, College Station, Texas). 
 
Interviews will be recorded with women’s permission and transcribed and analysed using the 
Framework method for thematic analysis 46.  Analyses will be deductively informed by the 
COM-B model for behaviour change41. , examining barriers and facilitators to weight 
management/intervention according to capability, opportunity and motivations. Themes that 
emerge inductively will be captured, and efforts made to identify and explore 
disconfirming/outlier cases.  Key topics and issues will be identified through familiarisation 
with transcripts by two researchers who will initially work independently and then together 
to discuss and agree the final coding framework with a third researcher. A series of thematic 
charts will be developed according to the coding framework, and data from each transcript 
summarized under each theme, enabling examination of similarities and differences of views 
within and between transcripts, and use of a constant comparative approach. Quantitative 
and qualitative data on acceptability of the intervention and other aspects of feasibility will 
be integrated using mixed methods matrices 46.  
 
Economic analysis 
 
Economic analyses will be conducted from an NHS/personal social services perspective on 
the assumption that if the intervention were commissioned for the target population, full 
costs would be met from NHS or local authority public health resources.  A review of 
evidence will be completed to assess if the wider evidence base would support economic 
modelling of impacts in a future study. 
 
Data on self-reported service use for specific service items will be collected using a modified 
version of the Adult Service Use Schedule (AD-SUS). Service use for individual items between 
intervention and control groups will compared descriptively (means, range and standard 
deviations). Service contacts will be costed using existing published unit cost data.  Trial 
participants allocated to the intervention will be allocated an intervention cost based on 
prices charged by the provider organisation.  Total costs from baseline to completion of 
follow-up (12 months) will be calculated for each participant as the sum of the cost of all 
service contacts plus intervention costs (for the intervention group).    
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Differences in mean total costs between trial groups will be evaluated through multivariate 
analysis controlling for baseline covariates. Interaction effects between the treatment 
allocation variable and variables identifying baseline BMI groupings will be used to test for 
sub-group effects.  The base-case analysis will evaluate the mean cost difference on a 
complete case basis and based on intention to treat (ITT).       
 
EQ-5D-5L data at baseline and follow-up will be used to evaluate quality of life outcomes in 
terms of a quality adjusted life year (QALY) equivalent over the 12 month follow-up period. 
Multivariate analysis will evaluate the mean difference in QALY outcomes between trial 
groups adjusting differences in baseline covariates. Mean QALY differences will be combined 
with mean cost-differences to evaluate cost-effectiveness on a complete case and ITT basis. 
Sampling uncertainty will be modelled using a simulated non-parametric bootstrap 
distribution of cost and QALY difference pairings within the cost-effectiveness plane and 
through subsequent generation of a cost-effectiveness acceptability curve (CEAC). 
 
Sensitivity analysis will include the effects of missing data on base-case conclusions and 
sensitivity of estimated mean cost differences to alternative multivariate modelling 
specifications; and sensitivity to departures to randomized treatment.    
 
Monitoring 
 
The trial will be supervised by an independent Trial Steering Committee (TSC).  An 
independent data monitoring committee (DMC) is not required to oversee the safety of 
subjects in the trial. As this is not a clinical trial of an investigational medical product, the TSC 
will take overall responsibility for trial conduct.  
 
Data management  
 
Quantitative data will be collected using specific study data collection forms, and processed 
and monitored centrally for consistency, viability and quality by the Core Project Team.  Data 
will be screened for out-of-range data, cross-checked for conflicting data within and between 
collection forms using computerised logic checking screens, and processed using a double 
data-entry system by an independent data clerk. The Trial Statistician will monitor data for 
consistency, viability and quality using a bespoke data management system (MedSciNet Ltd, 
Stockholm, Sweden). The MedSciNet programmer will run trial-specific programmes to 
extract certain fields from the database (as requested by the Chief Investigator or Trial 
Statistician), cross-check certain information, and with the Chief Investigator, review results 
generated for logic and any patterns or problems.   
 
 
Patient and Public Involvement 
The original research questions, study design, intervention and outcomes were developed 
with the support of six local women who had commenced pregnancy with a higher BMIs and 
had experienced support of weight management both during and after pregnancy.  To 
support the study as it progresses, four of these women will form an Expert Patient Group 
which will meet three times a year to discuss study progress, overcoming any barriers to 
15 
 
recruitment, content and completion of baseline and follow-up questionnaires, interview 
schedules, access and take up of the intervention, and implications of findings for a future 
definitive RCT.  All women recruited will be offered the opportunity to receive a summary 
report of the trial. 
 
 
 
Confidentiality 
 
All data from maternity records, questionnaires, interviews and from Slimming 
World®(Alfreton, UK)  on women’s attendance and weight management progress will be 
anonymised, kept confidential and managed in accordance with the Data Protection Acts 
1998 and 2018, NHS Caldicott Guardian, The Research Governance Framework for Health and 
Social Care and Research Ethics Committee Approval.  Each women will be allocated a unique 
study reference number. All records will be kept in a secure storage area with limited access. 
Clinical information will not be released without the written permission of the participant, 
except as necessary for monitoring and auditing by the Sponsor, its designee, Regularity 
Authorities, or the REC.  No patient identifiable data will be used in any publications or 
presentations relating to this study. 
 
 
Ethics and dissemination 
 
Study findings will be published in high impact journals, in line with CONSORT guidance47.  Our 
Expert PPI group will advise on dissemination of findings relevant for women and their 
families, in line with INVOLVE guidance.  Slimming World®(Alfreton, UK)  will have no access to 
trial data or be involved in any aspect of trial analysis or interpretation of trial results. The 
funders will have no role in trial analysis or interpretation of trial results.   
 
Discussion  
 
This feasibility trial is designed to provide robust data on whether it is possible to undertake 
a future definitive RCT of a postnatal weight management and lifestyle behaviour intervention 
among women from an ethnically diverse inner city setting.   Support for weight management 
is important, given the longer-term health impacts of a higher BMI at pregnancy 
commencement, or as a consequence of gaining EGWG, on women and their children, but 
evidence of how best to support these women is lacking.   Prior to undertaking a definitive 
RCT of effectiveness, evidence is needed to see if such a trial could be undertaken, if postnatal 
women would be prepared to enter a study of weight management, when would be an 
appropriate time to offer such an intervention, if a weight management intervention could 
impact on other positive health behaviours, confirm outcomes likely to be of most importance 
in a future trial and if criteria to proceed to a definitive trial have been met. 
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Table 1 Legend: Study objectives, outcomes, criteria for success and method of analysis 
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